Terug

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 11 mei 2010 - 07:55
  • Statutaire naam Crucell N.V.
  • Titel Crucell and NIH Announce Start of Malaria Vaccine Trial in Burkina Faso
  • Bericht Leiden, the Netherlands (May 11, 2010) – Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the start of a Phase I clinical study in Burkina Faso of its AdVac®-based malaria vaccine vector. Crucell is developing its malaria vaccine vector in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, and the Noguchi Memorial Institute for Medical Research at the University of Ghana.

Gerelateerde downloads

201005110000000008_2010 - 0511 Crucell and NIH Announce Start of Malaria Vaccine Trial in Burkina Faso.pdf

Datum laatste update: 06 oktober 2022

Informatie delen

Delen via: deel